Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
Forward 50 2013

Sue Friedman

Diagnosed at 33, Sue Friedman had already undergone treatment when she found out about the BRCA2 mutation that had given her a 9-in-10 chance of developing hereditary breast cancer.

Three years later, in 1999, Friedman founded FORCE: Facing Our Risk of Cancer Empowered, an organization advocating for awareness of hereditary breast and ovarian cancers. And they’ve had a pretty big year.

In April, the Supreme Court heard arguments about whether Myriad Genetics, Inc. had the right to patent the BRCA1 and BRCA2 genes. What seemed like an obscure matter was a life and death issue for many Ashkenazi women who, like Friedman, are far more likely to carry the mutation than the general population.

Friedman wrote an amicus brief to the court, expressing her concern at the implications of Myriad’s monopoly over the genes. Tests would be more expensive, and less accessible, she argued, because of the company’s control over research.

Then, in May, Angelina Jolie came out with a revelation in the opinion pages of the New York Times: After testing positive for a BRCA1 gene mutation, she had opted for a double mastectomy.

For activists like Friedman, 50, this was a long-awaited chance to bring attention to a health risk that she and others had been facing in silence and, mostly, alone.

Partly as a result of Friedman’s efforts, FORCE’s 15th anniversary will be a happy one: In June, the Supreme Court ruled that human DNA cannot be patented without being altered in some way, a victory for BRCA positive women.

A message from our CEO & publisher Rachel Fishman Feddersen

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.

At a time when other newsrooms are closing or cutting back, the Forward has removed its paywall and invested additional resources to report on the ground from Israel and around the U.S. on the impact of the war, rising antisemitism and polarized discourse.

Readers like you make it all possible. Support our work by becoming a Forward Member and connect with our journalism and your community.

—  Rachel Fishman Feddersen, Publisher and CEO

Join our mission to tell the Jewish story fully and fairly.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at [email protected], subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.